Palmitoyl Tetrapeptide-7 vs SHLP2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Side-by-Side Comparison
| Aspect | Palmitoyl Tetrapeptide-7 | SHLP2 |
|---|---|---|
| Mechanism | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. |
| Typical Dosage | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. |
| Administration | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. |
| Side Effects | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. |
| Best For |